06.12.15
Actuated Medical Inc. has signed a licensing agreement to develop Stanford University’s technology for cardiac atrial fibrillation. As a result of the arrangement, Actuated Medical has spun out a new company called Actuated Cardio Engineering in which Stanford University and its inventors are minority shareholders.
The National Science Foundation awarded a Phase II SBIR grant to Actuated Medical to help fund this project. Stanford received a sub-award of the grant to test the atrial fibrillation device. A team led by the device inventors will perform these pilot clinical studies at Stanford.
"I am excited to partner with Actuated Medical on this research and product development. I’ve focused on electrocardiology for 26 years and this new technology holds great promise to improve the treatment of atrial fibrillation," said Paul Wang, M.D., professor of Medicine at Stanford University Medical Center in California.
Actuated Cardio Engineering will conduct primary operations out of Actuated Medical’s research and manufacturing facilities in Bellefonte, Pa.
“It’s a pleasure to partner with Stanford. With NSF Phase II funding in place, we will jointly advance this technology toward commercialization," said Maureen L. Mulvihill, Ph.D., CEO of Actuated Medical. "With potential to drastically improve the ability to grip and navigate within the beating heart, this could be a major breakthrough in the treatment of cardiac atrial fibrillation.”
Actuated Medical develops minimally invasive instruments for clearing occlusions, penetrating tissue, and enabling the emerging MRI-guided surgical procedures.
The National Science Foundation awarded a Phase II SBIR grant to Actuated Medical to help fund this project. Stanford received a sub-award of the grant to test the atrial fibrillation device. A team led by the device inventors will perform these pilot clinical studies at Stanford.
"I am excited to partner with Actuated Medical on this research and product development. I’ve focused on electrocardiology for 26 years and this new technology holds great promise to improve the treatment of atrial fibrillation," said Paul Wang, M.D., professor of Medicine at Stanford University Medical Center in California.
Actuated Cardio Engineering will conduct primary operations out of Actuated Medical’s research and manufacturing facilities in Bellefonte, Pa.
“It’s a pleasure to partner with Stanford. With NSF Phase II funding in place, we will jointly advance this technology toward commercialization," said Maureen L. Mulvihill, Ph.D., CEO of Actuated Medical. "With potential to drastically improve the ability to grip and navigate within the beating heart, this could be a major breakthrough in the treatment of cardiac atrial fibrillation.”
Actuated Medical develops minimally invasive instruments for clearing occlusions, penetrating tissue, and enabling the emerging MRI-guided surgical procedures.